The Supreme Court on Thursday rejected a lawsuit challenging the Food and Drug Administration’s approach to regulating the abortion pill mifepristone with a ruling that will continue to allow the pills to be mailed to patients without an in-person doctor’s visit.
Alternative headline: US Supreme Court surprised all by agreeing with the bare minimum and not forcing partisan political opinions into laws.